Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Lopalco

Showing results (191-200 of 221) with videos related to

Pageof 23
Sort By:
Seminars in Arthritis and Rheumatism|January 31, 2026
VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registriesFrancesco Gavioli, Valeria Caggiano, Jessica Sbalchiero, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Seminars in Arthritis and Rheumatism|March 30, 2024
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registryAntonio Vitale, Valeria Caggiano, Eduardo Martin-Nares, et al.
Journal of Autoimmunity|March 27, 2025
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative studyIrene Mattioli, Maria Letizia Urban, Roberto Padoan, et al.
RMD Open|November 21, 2023
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease RegistryPiero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Frontiers in Medicine|December 27, 2023
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's DiseaseAntonio Vitale, Valeria Caggiano, Petros P Sfikakis, et al.
Frontiers in Medicine|January 28, 2026
Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registriesValeria Caggiano, Jessica Sbalchiero, Micol Frassi, et al.
Frontiers in Medicine|April 25, 2022
Development and Implementation of the AIDA International Registry for Patients With Still's DiseaseAntonio Vitale, Francesca Della Casa, Giuseppe Lopalco, et al.
Frontiers in Pharmacology|March 24, 2025
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA networkAntonio Vitale, Flavia Leone, Valeria Caggiano, et al.
Rheumatology (Oxford, England)|April 2, 2025
Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network RegistryAntonio Vitale, Valeria Caggiano, Jessica Sbalchiero, et al.
Pageof 23

Showing results (191-200 of 221) with videos related to

Sort By:
Pageof 23
Seminars in Arthritis and Rheumatism|January 31, 2026
VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registriesFrancesco Gavioli, Valeria Caggiano, Jessica Sbalchiero, et al.
Frontiers in Pharmacology|March 6, 2025
Efficacy and safety profile of biotechnological agents and Janus kinase inhibitors in VEXAS syndrome: data from the international AIDA Network VEXAS registryAntonio Vitale, Valeria Caggiano, Flavia Leone, et al.
Seminars in Arthritis and Rheumatism|March 30, 2024
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registryAntonio Vitale, Valeria Caggiano, Eduardo Martin-Nares, et al.
Journal of Autoimmunity|March 27, 2025
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative studyIrene Mattioli, Maria Letizia Urban, Roberto Padoan, et al.
RMD Open|November 21, 2023
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease RegistryPiero Ruscitti, Francesco Masedu, Antonio Vitale, et al.
Frontiers in Medicine|December 27, 2023
Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's DiseaseAntonio Vitale, Valeria Caggiano, Petros P Sfikakis, et al.
Frontiers in Medicine|January 28, 2026
Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registriesValeria Caggiano, Jessica Sbalchiero, Micol Frassi, et al.
Frontiers in Medicine|April 25, 2022
Development and Implementation of the AIDA International Registry for Patients With Still's DiseaseAntonio Vitale, Francesca Della Casa, Giuseppe Lopalco, et al.
Frontiers in Pharmacology|March 24, 2025
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA networkAntonio Vitale, Flavia Leone, Valeria Caggiano, et al.
Rheumatology (Oxford, England)|April 2, 2025
Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network RegistryAntonio Vitale, Valeria Caggiano, Jessica Sbalchiero, et al.
Pageof 23